Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Vote On Adverse Event Reporting Bill Expected By October

This article was originally published in The Tan Sheet

Executive Summary

The Senate likely will vote on the "Dietary Supplement & Nonprescription Drug Consumer Protection Act" (S 3546) before they adjourn in early October, according to several supplement industry trade groups

You may also be interested in...



Cleveland Clinic’s Nissen Asks HELP Panel For Stronger Supplement Regulation

Pending legislation on adverse event reporting does not go far enough in expanding regulatory oversight of dietary supplements, the American College of Cardiology president told a Senate committee Nov. 16

Cleveland Clinic’s Nissen Asks HELP Panel For Stronger Supplement Regulation

Pending legislation on adverse event reporting does not go far enough in expanding regulatory oversight of dietary supplements, the American College of Cardiology president told a Senate committee Nov. 16

Cleveland Clinic’s Nissen Asks HELP Panel For Stronger Supplement Regulation

Pending legislation on adverse event reporting does not go far enough in expanding regulatory oversight of dietary supplements, the American College of Cardiology president told a Senate committee Nov. 16

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099767

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel